Open Telugu dataWhat the apps compute with, and where it came from

Medicine ceiling prices

The most a maker may charge for each scheduled medicine, per tablet, ml or other unit, excluding GST, as NPPA's order fixes it. Brands may have their own price fixed separately; NPPA's Pharma Sahi Daam shows them.

Velugu

Medicine ceiling prices, National List of Essential Medicines 2022

Not yet confirmed National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers · Order S.O. 1575(E) dated 2026-03-25, Gazette of India Extraordinary, Part II, Section 3(ii): Price Revision as per Annual Wholesale Price Index (WPI) @ 0.64956% increase.

Official source still to compare with: The rows compared by a person with NPPA's order (the PDF, sha256 8c974127f5518cf2a31eb1a7ea69fefa4fbb161ea3a58823e9a5d2587bf7897c); the script has compared every cell (specs/013-medicine-ceiling-prices/verify.md).

Order S.O. 1575(E), 25 March 2026. 767 formulations, 347 medicines.

Read from the file SO-1575E-2026-03-25.pdf (sha256 8c974127f5518cf2…); every cell compared with it.

The order's own notes, word for word

  1. The ceiling prices are applicable with effect from 1.4.2026 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 0.64956% for the year 2025 over 2024).
  2. In respect of formulation where pack wise ceiling price is notified, for any other pack size manufactured, the manufacturer shall approach NPPA under para 11(3) of DPCO, 2013 for specific price approval for its formulations.
  3. In respect of any other scheduled formulation, for which ceiling price is not mentioned above, the manufacturer shall approach NPPA for specific price approval for its formulations.
  4. All manufacturers of scheduled formulations, selling branded or generic or both the versions of scheduled formulations at price higher than the ceiling price (plus Goods and Services Taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Taxes as applicable, if any.
  5. All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O. & date as specified in column 6 (a) & 6 (b) in the above table (plus Goods and Services Taxes as applicable, if any), may revise the existing MRP of their formulations, on the basis of WPI @ 0.64956% for year 2025 over 2024 in accordance with paragraph 16(2) of DPCO, 2013.
  6. The manufacturers may add Goods and Services Taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.
  7. The formulation of Sodium Valproate includes combination of Sodium Valproate and Valproic Acid both together corresponding to Sodium Valproate of the stated strength.
  8. The ceiling prices fixed for Enoxaparin Injection 40mg/0.4ml and 60 mg/0.6 ml at S.N. 287 are also applicable to any other strengths (such as 300mg/3ml, 80mg/0.8ml, 20mg/0.2ml etc.) of the Enoxaparin with same ratio i.e.10mg/0.1ml.
  9. The ceiling prices fixed for Paclitaxel Injection 30 mg/5 mL and 100mg/16.7 ml at S.N. 567 are also applicable to any other strengths (300mg/50ml, 260mg/43.4ml, 250mg/41.7ml, 200mg/33.4ml etc.) of the Paclitaxel with same ratio i.e. 6mg/ml.
  10. The ceiling prices fixed for Budesonide Respirator solution for use in nebulizer 0.5mg/mL and Budesonide Respirator solution for use in nebulizer 1mg/mL (mentioned at S.N. 109 and 110) are also applicable to 2ml respules of 0.5mg and 2ml respules of 1mg by applying 2 times of the ceiling prices of 1 ml respules of 0.5 mg and 1 mg respectively.
  11. Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non-revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), along with interest thereon from the date of overcharging.
  12. The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
  13. As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
  14. Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
  15. The manufacturers of above said scheduled formulations shall furnish quarterly return to NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
  16. The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
  17. Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

Source's terms

NPPA: "Material featured on this site may be reproduced free of charge in any format or media without requiring specific permission", accurately, not in a derogatory or misleading context, with the source prominently acknowledged (nppa.gov.in/en/copyrightpolicy). The order is published in the Gazette of India (Copyright Act 1957, s. 52(1)(q)(i)). Figures as the order gives them, read from its PDF.